The Impact of Artemether-Lumefantrine on Genes Associated With Antimalarial Resistance
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00440752|
Recruitment Status : Completed
First Posted : February 27, 2007
Last Update Posted : March 26, 2008
|Condition or disease|
|Falciparum Malaria Antimalarials|
In Sudan the current treatment protocol includes two artemisinin combinations (ACT); artesunate + sulphadoxine/pyrimethamine (AS/SP) as first line and artemether-lumefantrine (AL) as second line. This protocol has been implemented in 2004, since then various studies have reported the high efficacy of both combinations (e.g. Adam et al., 2005; Elamin et al., 2005; Mohamed et al., 2006).
However, there has been no report of the impact of these combinations on drug resistance markers in Sudan. Data from other African countries has shown that AL selects for certain alleles in the pfmdr-1 gene (Sisowath et al., 2005, Dokomajilar et al., 2006; Humphreys et al., 2007), but the impact on the prevalence of different pfcrt and pfmdr-1alleles remains unclear. It is essential to monitor ACT efficacy in addition to identify molecular markers that are associated with response to different drugs to facilitate epidemiological surveys for evidence based decision making. Recent work in The Gambia suggests that transmission-related endpoints, such as emergence of gametocytes after treatment, may be better indicators of emerging drug resistance (Hallett et al., 2006).
The aim of the proposed study is to examine the impact of treatment with artemether-lumefantrine (AL) on alleles of pfcrt and pfmdr-1 in P. falciparum isolates in an area of marked seasonal transmission in eastern Sudan. Most studies of resistance markers measure marker prevalence by DNA amplification, but we will also investigate gene expression using quantitative amplification of mRNA encoding pfcrt and pfmdr-1. The impact of genotype and gene expression levels on treatment outcome, and on the emergence and density of peripheral gametocytes will be examined.
|Study Type :||Observational|
|Actual Enrollment :||100 participants|
|Official Title:||The Impact of Artemether-Lumefantrine on Genes Associated With Antimalarial Resistance in an Area of Seasonal Transmission|
|Study Start Date :||October 2006|
|Actual Study Completion Date :||December 2006|
Cohort of study participants receiving treatment with artemether-lumefantrine
- Levels of expression of pfcrt and pfmdr-1 alleles on day 0, 3, 7, 14, 21, 28 detected by real-time PCR. [ Time Frame: 2007 to 2009 ]
- Parasitological failure occurring at day 3, 7, 14, 21, 28 or any other day during this period. [ Time Frame: within 28 days of subject recruitment ]
- Gametocyte development detected by reverse transcriptase PCR on day 0, 3, 14 and 28 [ Time Frame: 2008 to 2009 ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00440752
|Tropical Medicine Research Institute|
|Khartoum, Sudan, 11111|
|Principal Investigator:||Colin Sutherland, PhD.||London School of Hygiene and Tropical Medicine|
|Study Chair:||Badria B El-Sayed, PhD||Tropical Medicine Research Institute|